Catalyst Pharmaceuticals Net Worth

Catalyst Pharmaceuticals Net Worth Analysis

Catalyst Pharmaceuticals Target Price Consensus

Catalyst Pharmaceuticals Target Price Projection

Catalyst Pharmaceuticals' current and average target prices are 15.11 and 23.10, respectively. The current price of Catalyst Pharmaceuticals is the price at which Catalyst Pharmaceuticals is currently trading. On the other hand, Catalyst Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Catalyst Pharmaceuticals and the information provided on this page.

Know Catalyst Pharmaceuticals' Top Institutional Investors

Note, although Catalyst Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Catalyst Pharmaceuticals' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.76 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Catalyst Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Catalyst Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Project Catalyst Pharmaceuticals' profitablity

The company has Profit Margin (PM) of 0.18 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate Catalyst Pharmaceuticals' management efficiency

Catalyst Pharmaceuticals has return on total asset (ROA) of 0.1283 % which means that it generated a profit of $0.1283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2075 %, meaning that it created $0.2075 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.27 in 2024. Return On Capital Employed is likely to rise to 0.23 in 2024. At this time, Catalyst Pharmaceuticals' Asset Turnover is fairly stable compared to the past year.

Catalyst Pharmaceuticals Corporate Filings

Catalyst Pharmaceuticals time-series forecasting models is one of many Catalyst Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Catalyst Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Catalyst Pharmaceuticals Earnings Estimation Breakdown

The calculation of Catalyst Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Catalyst Pharmaceuticals is estimated to be 0.17 with the future projection ranging from a low of 0.14 to a high of 0.19. Please be aware that this consensus of annual earnings estimates for Catalyst Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.

Catalyst Pharmaceuticals Earnings Projection Consensus

Catalyst Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Catalyst Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Catalyst Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Catalyst Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Catalyst Pharmaceuticals Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Catalyst Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Catalyst Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

Catalyst Quarterly Analyst Estimates and Surprise Metrics

Be your own money manager

Our tools can tell you how much better you can do entering a position in Catalyst Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Catalyst Pharmaceuticals Corporate Directors

Catalyst Pharmaceuticals corporate directors refer to members of a Catalyst Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Catalyst Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Catalyst Pharmaceuticals' board members must vote for the resolution. The Catalyst Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Catalyst Stock?

The net worth of Catalyst Pharmaceuticals is the difference between its total assets and liabilities. Catalyst Pharmaceuticals' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Catalyst Pharmaceuticals' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Catalyst Pharmaceuticals' net worth can be used as a measure of its financial health and stability which can help investors to decide if Catalyst Pharmaceuticals is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Catalyst Pharmaceuticals stock.

Already Invested in Catalyst Pharmaceuticals?

When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock:

How To Invest In Catalyst Details

Is Catalyst Stock a good investment? Details

What is Catalyst Pharmaceuticals' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Complementary Tools for Catalyst Stock analysis

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details